Indiana Medicaid Drug Utilization Review Board Newsletter
|
|
- Miranda McKinney
- 5 years ago
- Views:
Transcription
1 Indiana Medicaid Drug Utilization Review Board Newsletter Indiana Medicaid DUR Board Room W382 Indiana State Government Center, South Introduction The Management of Type 2 Diabetes Deborah K. Brokaw, Pharm.D., BCACP Diabetes is a chronic, progressive, metabolic disease that affects over West Washington million people in the United States. An additional 7 million are estimated to be Street undiagnosed. 1 It is the seventh leading cause of death and is associated with significant morbidity, such as kidney failure, blindness, non-traumatic lowerlimb amputations, cardiovascular disease and stroke. 1 In 2007, estimated Indianapolis, Indiana diabetes costs in the United States totaled $174 billion, with $116 billion attributed directly to medical costs. 1 The increasing prevalence of type 2 DUR Board Members diabetes (T2DM) mirrors the changes in lifestyle (lack of diet and exercise) and rising obesity rates in the U.S. population. 2 This newsletter will review pertinent information on the management of type 2 diabetes, current guideline recommendations, and highlight the importance of medication adherence.!"# # $ # # % # &' (!)% *! () Inside this Issue The Management of Type 2 Diabetes Top 25 Drug Lists for 3Q2012 Epidemiology Type 2 diabetes accounts for 90-95% of patients with the diagnosis of diabetes. 1 Although T2DM is referred to as adult onset diabetes, the incidence in children and adolescents has been increasing. 1 During , an estimated 3,600 youth were newly diagnosed on an annual basis with type 2 diabetes. 1 Risk factors for the development of T2DM include: older age, obesity, family history of diabetes, history of gestational diabetes, impaired glucose metabolism, physical inactivity, and race/ethnicity (African Americans, Hispanic/Latino Americans, American Indians, Asian Americans, and Pacific Islanders). 1,3 Diagnosis Diabetes can be diagnosed using four different measures (Table 1). These include using the fasting plasma glucose (FPG), 2-hour value in the oral glucose tolerance test (OGTT), and hemoglobin A1c (A1C). 3 If an A1C is being used for diagnosis, it should be performed in a laboratory setting using a method that is certified using the National Glycohemoglobin Standardization Program or traceable to the Diabetes Control and Complications Trial reference assay. 3
2 VOLUME 16 ISSUE 1 PAGE 2 Table 1. Criteria for the Diagnosis of Diabetes 3 Any of the following: A1C > 6.5%* FPG > 126 mg/dl* 2-h plasma glucose > 200 mg/dl following a 75g glucose load* Random plasma glucose > 200 mg/dl in a patient with classic symptoms of hyperglycemia *If the patient has a test result that is diagnostic for diabetes, the result should be confirmed, preferably using the same test, on a subsequent day. Lifestyle Modifications All patients with T2DM benefit from physical activity and improvements in diet. These benefits include weight loss, improvements in blood glucose, and also reductions in cardiovascular risk factors. 2,3 Upon diagnosis, patients should be educated and receive encouragement on increasing physical activity and personalized dietary advice. This should be reassessed and reinforced at subsequent visits. In general, patients with T2DM should spend at least 150 min/week on moderate-intensity aerobic activity, spread over at least 3 days per week with no more than 2 consecutive days without exercise. 3 Patients should also be encouraged to engage in resistance training twice a week in the absence of contraindications. 3 Medical nutrition therapy is an integral part of diabetes management and patients should be encouraged to meet with a certified diabetes educator or dietician to receive education on healthy eating and individualized dietary recommendations. Patients should be reminded that lifestyle modifications enhance the efficacy of pharmacologic therapy and even modest weight loss (5-10%) can significantly improve glycemic control. 2,3 Diabetes Pharmacotherapy The goal of drug therapy is to lower blood glucose in an effort to minimize long-term complications while avoiding hypoglycemia. 2,4 Effective management of diabetes is important, because the risk of microvascular and macrovascular complications increase as the A1C increases. 2,3 To delay the onset and/or progression of these complications a multifactorial approach is needed, since glycemic control is critical. In patients with T2DM there are several pathophysiologic defects that contribute to hyperglycemia. These include: increased hepatic glucose production, abnormal islet cell function (pancreatic - and -cell dysfunction), abnormalities in the incretin system, and insulin resistance in target tissues (liver, myocardium, skeletal muscle, adipose tissue). 2-4 Current drug therapy targets these underlying physiological defects and can be divided into three general categories: therapies that increase insulin levels, improve insulin sensitivity, and those with other actions (Table 2).
3 VOLUME 16 ISSUE 1 PAGE 3 adapted from references 3,4 Table 2. Pharmacologic Therapies for Type 2 Diabetes Medication Class Action(s) Expected A1C Lowering Oral Advantages Disadvantages Biguanides (Metformin) hepatic glucose production intestinal glucose absorption action of insulin % No weight gain, no hypoglycemia (monotherapy), improvements in lipid panel, reduction in cardiovascular events, combination products available, cost Gastrointestinal intolerance, increased risk of lactic acidosis (rare), vitamin B 12 deficiency, contraindicated in patients with renal impairment 2 nd generation Sulfonylureas (Glyburide, Glipizide, Glimepiride) insulin secretion % Well tolerated, combination products available, cost Hypoglycemia, weight gain Thiazolidinediones (Pioglitazone, Rosiglitazone) Meglitinides (Nateglinide, Repaglinide) peripheral insulin sensitivity % No hypoglycemia (monotherapy), improvements in HDL and triglycerides (pioglitazone), combination products available insulin secretion % Short duration of action, hepatic clearance, targets postprandial hyperglycemia, combination tablets available Weight gain, edema, heart failure, increased risk of fractures, potential risk of bladder cancer and cardiovascular events (rosiglitazone), cost Hypoglycemia, weight gain, dosing frequency, cost Alpha-glucosidase inhibitors (Acarbose, Miglitol) slowed intestinal carbohydrate digestion and absorption % Targets postprandial hyperglycemia Gastrointestinal intolerance, dosing frequency DPP-4 inhibitors (Linagliptin, Saxagliptin, Sitagliptin) active GLP-1 and GIP concentrations insulin secretion % No weight gain, no hypoglycemia (monotherapy), combination products available, infrequent adverse effects Unknown long-term safety, reported cases of pancreatitis and angioedema, cost Bile acid sequestrant (Colesevelam) glucagon secretion unknown 0.5% No hyperglycemia, LDL lowering Constipation, drug interactions, dosing frequency, may increase triglycerides, cost D2 dopamine-receptor agonist (Bromocriptine rapid release) alters hypothalamic metabolism regulation insulin sensitivity 0.5% Hypoglycemia rare Adverse effects (gastrointestinal, fatigue, dizziness, rhinitis), unknown long-term safety, cost DPP: dipeptidyl peptidase; GLP-1: glucagon-like peptide-1; GIP: glucose-dependent insulinotropic polypeptide
4 VOLUME 16 ISSUE 1 PAGE 4 adapted from references 3,4 Continued. Table 2. Pharmacologic Therapy for Type 2 Diabetes Injectable GLP-1-receptor agonist (Exenatide, Exenatide ER, Liraglutide) insulin secretion (dosedependent) glucagon secretion (dosedependent) % No hypoglycemia (monotherapy), weight loss Gastrointestinal intolerance, reported cases of pancreatitis, thyroid C-cell hyperplasia and tumors in rodents (exenatide ER and liraglutide), injection, unknown long-term safety, cost Slowed gastric emptying satiety Amylin analogue (Pramlintide) glucagon secretion (dosedependent) Slowed gastric emptying % Weight loss, targets postprandial hyperglycemia Hypoglycemia with insulin use, nausea and vomiting, injection, dosing frequency, unknown long -term safety, cost satiety Insulin (Aspart, Glulisine, Lispro, Regular, NPH, Detemir, Glargine) glucose disposal hepatic glucose production % Effective in all patients, potent hypoglycemic effect, (theoretically unlimited), several preparations, combination products available Hypoglycemia, weight gain, Injection, cost (newer agents), patient education needed with use GLP-1: glucagon-like peptide-1; ER: extended-release Therapies which increase the levels of insulin include: sulfonylureas, meglitinides, glucagon-like peptide- 1 (GLP-1) agonists, dipeptidyl peptidase-4 (DPP-4) inhibitors, and exogenous insulin. With the exception of the GLP-1 agonists and the DPP-4 inhibitors, these agents are available generically and can cause weight gain and hypoglycemia when used as monotherapy. 2,4 The meglitinides have a shorter duration of action, target primarily postprandial blood glucose, but require dosing at meals and bedtime. 2,4 The GLP-1 agonists and DPP-4 inhibitors are newer incretin agents which offer several advantages. As monotherapy they lack the risk of hypoglycemia and are not associated with weight gain. 2,4 The GLP-1 agonists promote weight loss, but cause nausea and vomiting upon initiation, and have been associated with acute pancreatitis. 2,4,9 DPP-4 inhibitors are weight neutral and have an adverse effect profile similar to placebo. 4,9 However, concerns over post-marketing reports of severe hypersensitivity reactions are associated with their use. 9 This lack of longterm safety data with the incretin therapies is a disadvantage associated with their use. Insulin is the most potent agent for lowering blood glucose and can be used in T2DM patients as monotherapy or in combination with oral anti-diabetic agents to lower blood glucose. 4 Insulin is often required in patients with T2DM, as a result of progressive β-cell dysfunction, to reach and maintain glycemic goals. 2 Since there are several formulations of insulin on the market (long-, short-, and rapid-acting), patient characteristics (lifestyle, exercise/dietary habits) and blood glucose trends from self-monitoring of blood glucose (SMBG) should be taken into consideration when insulin therapy is initiated. 2 A common initial strategy is the addition of a basal insulin (i.e., NPH, glargline, detemir) to the existing treatment regimen (often at bedtime) to suppress hepatic glucose production in between meals and at nighttime. 2,4 If glycemic goals are not reached, rapid-acting insulin can be utilized. 2,4
5 VOLUME 16 ISSUE 1 PAGE 5 Therapies such as metformin and thiazolidendiones (TZDs) enhance insulin sensitivity. Unlike the TZDs, metformin is not associated with weight gain and may result in weight loss. In addition to being first-line therapy, it offers several advantages in the treatment of T2DM. It is available in combination products with many anti-diabetic agents and as an extended-release product which helps simplify complicated drug therapy regimens. 2,3 Even though TZDs enhance insulin sensitivity in peripheral tissues, their adverse effect profile and long-term safety is concerning. These include: exacerbation of heart failure, increased risk of bone fractures, and recent associations of bladder cancer with pioglitazone. 2,4 While pioglitazone continues to be available, rosiglitazone can only be obtained through a restricted assess program due to concerns over increased risk of myocardial infarction. 9 Other therapies available for T2DM work through alternative mechanisms to lower blood glucose, and have lower utilization due to modest lowering of A1C levels and/or adverse effects. Alpha-glucosidase inhibitors slow the absorption of carbohydrates from the intestines, but their use is limited by their dosing regimen and gastrointestinal adverse effects. 2,4 Bromocriptine is a dopamine agonist which increases insulin sensitivity through an unknown mechanism. 4 Its place in the therapy for T2DM has yet to be determined, and because only the immediate-release formulation of bromocriptine is approved for this indication, cost may be an issue. 4 Colesevelam is a bile acid sequestrant which reduces hepatic glucose production by an unknown mechanism and also increases incretin levels. 2,4 Even though patients have to take 6 tablets per day to get a small reduction in A1C, colesevelam can positively impact LDL and HDL cholesterol levels. 2,4,9 The amylin mimetic pramlintide stimulates amylin receptors, and like GLP-1 agonists, is an injectable therapy that causes weight loss, decreases appetite, delays gastric emptying, and decreases glucagon secretion (independent of glucose levels). 2 It is indicated for use in patients with either type 1 or type 2 diabetes who use mealtime insulin therapy. 9 When used in conjunction with insulin, especially in patients with type 1 diabetes, severe hypoglycemic episodes have been reported. 9 Treatment Approach The American Diabetes Association (ADA) recommends an individualized patient-centered approach to treat T2DM. This involves using lifestyle modifications (diet and exercise) and pharmacologic therapy to achieve an A1C goal of < 7%, for most individuals. 2,3 If initiated soon after the diagnosis of diabetes, lowering the A1C to < 7% has been shown to reduce microvascular complications of diabetes, and has been associated with long-term reduction in macrovascular disease. 3 Unfortunately, data from the National Health and Nutrition Examination Survey ( ) published in 2009 showed that only 57% of adults with diabetes achieved an A1C < 7%. 5 Some patient populations may require a higher or lower A1C goal therefore, healthcare providers should take into consideration patient-specific characteristics (e.g., concomitant disease states, disease duration, life expectancy, patient attitude, patient resources, and risks associated with hypoglycemia) when deciding on glycemic goals for their patients. 2,,3 Because the achievement of glycemic goals requires active patient participation, involving patients in the decision making process can be helpful and may improve adherence to the management plan. 6 The recently updated ADA and European Association for the Study of Diabetes treatment guidelines recommend early intervention with metformin in combination with lifestyle changes. 2,3 Unless contraindications exist, metformin should be considered the optimal first-line drug. This recommendation is based upon metformin s effect on A1C, absence of weight gain or hypoglycemia, generally low level of adverse effects, relatively low cost, and potential beneficial effects on cardiovascular disease. 2,7,8 To minimize gastrointestinal symptoms during treatment initiation, metformin should be given with meals and titrated up from a low dose. In addition, because metformin can increase the risk of lactic acidosis, its use is contraindicated in patients with renal impairment (serum creatinine > 1.4mg/dl in females, > 1.5 mg/dl in males) and should not be used in patients at risk for lactic acidosis (e.g., alcoholism, acute/chronic metabolic acidosis, acute or unstable congestive heart failure). 9 Patients with a high baseline A1C ( > 9%) may require combination therapy with two oral agents or insulin. 2
6 VOLUME 16 ISSUE 1 PAGE 6 Because T2DM is a chronic, progressive disease, patients will ultimately need combination drug therapy to achieve and maintain target A1C levels. In these instances factors such as cost, concomitant conditions, drug therapy, and lifestyle should be taken into consideration since there is not a consensus on which therapy should be added to metformin. 2,3 If after 3 months of monotherapy at maximal tolerated doses the A1C is not at target levels, and medication adherence is not a contributing factor, a second therapy should be considered. Options could include adding on a second oral agent, a GLP-1 agonist, or basal insulin. 2,3 In general, the addition of an oral agent provides a further A1C reduction of approximately 1%. 2 However, if initial therapy did not produce any clinically significant lowering of the A1C, it should be replaced with an agent with a different mechanism of action. 2 It is important to note, that the greater the A1C lowering that a patient needs, the more likely the addition of insulin will be needed. This is especially true when the addition of a third agent is needed to achieve glycemic control. Monitoring The A1C should generally be monitored twice a year in patients meeting their glycemic goals and quarterly in patients requiring drug therapy changes or who have not achieved their goal A1C. 2,3 Patients and healthcare providers can also utilize SMBG to assess glycemic control, especially postprandial blood glucose targets, in those patients using multiple insulin injections. 3 The optimal frequency and timing of SMBG in patients with T2DM has yet to be determined. Recommended goals include pre-prandial plasma glucose levels of mg/dl and postprandial plasma glucose levels < 180 mg/dl. 3 Medication Adherence Medication adherence is an important component in achieving glycemic goals. Poor glycemic control is associated with worse patient outcomes, including increased risk of hospitalizations, and potentially increased treatment costs. 5 Even though A1C levels improve as medication adherence increases, adherence rates as low as 65% for oral anti-diabetic medications have been reported. 6 Commonly reported reasons for non-adherence with anti-diabetic medications include: adverse effects (e.g., hypoglycemia, weight gain, gastrointestinal symptoms), medication cost, fear of self-injections (with injectable therapies), complex treatment regimens, and lack of patient understanding of medication regimen. 6 Unfortunately, healthcare providers are often not aware of non-adherence; therefore, it is important for them to ask about and discuss medication adherence with patients. This can result in a more open dialogue between the patient and provider and create an opportunity for providers to openly discuss issues related to patient adherence and potential barriers. In addition to involving patients in the decision-making process with their medications, ways to improve medication adherence include, selecting medications with less frequent daily dosing (e.g. once daily with ER formulations), decreasing the number of tablets taken daily by using combination tablets if available, using generic products, and titrating the dose of the medication slowly to improve tolerability (e.g., metformin, GLP- 1 agonist). 6 Discussions regarding potential adverse effects and their management, dosing regimen, and cost are additional ways to encourage adherence with patients. 6 Conclusion Diabetes is a chronic, progressive disease that affects many people and has a large impact on healthcare costs. Several medications can be used to manage diabetes and the symptoms associated with it. Current treatment guidelines recommend metformin, in addition to lifestyle modifications, as first-line therapy. However, many patients will require additional add-on therapies to achieve and maintain optimal glycemic control. For successful, comprehensive, and ongoing treatment, patients with diabetes should take an active role in managing their disease and build strong partnerships with their doctor and other healthcare providers.
7 VOLUME 16 ISSUE 1 PAGE 7 For additional information on Diabetes and patient education materials, please visit the following websites: American Academy of Family Physicians American Diabetes Association Centers for Disease Control and Prevention National Diabetes Education Program References 1. Centers for Disease Control and Prevention. National diabetes fact sheet: national estimates and general information on diabetes and prediabetes in the United States, Atlanta, GA: U.S. Department of Health and Human Services, Centers for Disease Control and Prevention, Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care 2012;35: American Diabetes Association. Position Statement: Standards of Medical Care in Diabetes Diabetes Care 2012;35(Suppl 1):S11-S Ismail-Beigi. Glycemic management of type 2 diabetes mellitus. N Engl J Med 012;366(14): Wild H. The Economic Rationale for Adherence in the Treatment of Type 2 Diabetes Mellitus. Am J Manag Care. 2012;18:S43-S Nau D. Recommendations for Improving Adherence to Type 2 Diabetes Mellitus Therapy Focus on Optimizing Oral and Non-Insulin Therapies. Am J Manag Care. 2012;18:S49-S Turner RC, Holman RR, Cull CA, et al;uk Prospective Diabetes Study (UKPDS) Group. Effect of intensive bloodglucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 1998;352: Lamanna C, Monami M, Marchionni N, et al. Effect of metformin on cardiovascular events and mortality: a metaanalysis of randomized clinical trials. Diabetes Obes Metab 2011;13(3): Individual package insert
8 VOLUME 16 ISSUE 1 PAGE 8 Top 25 Drugs For 3rd Quarter 2012 Top 25 Drugs 3rd Quarter 2012 Ranked by Total Number of Paid Claims Drug # Paid Claims Avg. Amount Paid/Claim LORATADINE 10 MG TABLET 49,028 $4.75 PROAIR HFA 90 MCG INHALER 48,948 $50.11 HYDROCODON-ACETAMINOPHEN ,893 $2.78 OMEPRAZOLE DR 20 MG CAPSULE 35,636 $6.09 HYDROCODON-ACETAMINOPHEN ,688 $8.65 TRAMADOL HCL 50 MG TABLET 29,596 $2.72 ALPRAZOLAM 1 MG TABLET 25,851 $2.57 CETIRIZINE HCL 10 MG TABLET 25,841 $6.89 AMOXICILLIN 400 MG/5 ML SUSP 23,301 $8.49 CYCLOBENZAPRINE 10 MG TABLET 22,287 $2.41 HYDROCODON-ACETAMINOPHN ,071 $14.63 ALBUTEROL 0.083% INHAL SOLN 21,964 $14.61 DOK 100 MG CAPSULE 20,949 $2.19 FERROUS SULFATE 325 MG TABLET 20,846 $0.44 CLONAZEPAM 1 MG TABLET 20,366 $2.56 MAPAP 325 MG TABLET 20,072 $1.65 ALPRAZOLAM 0.5 MG TABLET 19,407 $2.31 FLUTICASONE PROP 50 MCG SPRAY 19,084 $22.47 CLONAZEPAM 0.5 MG TABLET 18,746 $1.93 CEPHALEXIN 500 MG CAPSULE 17,044 $4.02 AZITHROMYCIN 250 MG TABLET 16,856 $5.05 ASPIRIN 81 MG CHEWABLE TABLET 16,508 $1.44 OMEPRAZOLE DR 40 MG CAPSULE 16,189 $12.47 IBUPROFEN 800 MG TABLET 15,342 $3.34 HYDROCODON-ACETAMINOPH ,301 $6.76
9 VOLUME 16 ISSUE 1!"# PAGE 9 Top 25 Drugs 3rd Quarter 2012 Ranked by Amount Paid Drug Total Amount Paid Avg. Amount Paid/Claim ABILIFY 5 MG TABLET $3,197, $ CYMBALTA 60 MG CAPSULE $3,138, $ ABILIFY 10 MG TABLET $2,545, $ PROAIR HFA 90 MCG INHALER $2,452, $50.11 ADVATE UNITS VIAL $2,367, $34, METHYLPHENIDATE ER 36 MG TAB $1,986, $ LANTUS 100 UNITS/ML VIAL $1,812, $ SPIRIVA 18 MCG CP-HANDIHALER $1,641, $ ABILIFY 20 MG TABLET $1,601, $ INCIVEK 375 MG TABLET $1,579, $17, SUBOXONE 8 MG-2 MG SL FILM $1, $ ABILIFY 15 MG TABLET $1,433, $ INTUNIV ER 2 MG TABLET $1,398, $ VYVANSE 30 MG CAPSULE $1,289,076,85 $ METHYLPHENIDATE ER 54 MG TAB $1,203, $ ADVATE UNITS VIAL $1,186, $31, SINGULAIR 10 MG TABLET $1,179, $ DEXTROAMP-AMPHET ER 20 MG CAP $1,162, $ PULMOZYME 1 MG/ML AMPUL $1,139, $2, COPAXONE 20 MG INJECTION KIT $1,131, $4, CYMBALTA 30 MG CAPSULE $1,100, $ ABILIFY 2 MG TABLET $1,098, $ DEXTROAMP-AMPHET ER 30 MG CAP $1,093, $ ATRIPLA TABLET $1,087, $2,352.97
10 VOLUME 16 ISSUE 1 PAGE 10 PDL Listing The Indiana Medicaid PDL listing may be found at the following Web site: Program Assistance All prior authorization requests or questions regarding the PDL should be directed to the Xerox (formerly ACS) Clinical Call Center at The article in this issue of the DUR Newsletter was authored by Debbie Brokhaw PharmD, Clinical Pharmacist, Xerox The content of this newsletter was approved by the Indiana Medicaid DUR Board
Reviewing Diabetes Guidelines. Newsletter compiled by Danny Jaek, Pharm.D. Candidate
Reviewing Diabetes Guidelines Newsletter compiled by Danny Jaek, Pharm.D. Candidate AL AS KA N AT IV E DI AB ET ES TE A M Volume 6, Issue 1 Spring 2011 Dia bet es Dis pat ch There are nearly 24 million
More informationOBJECTIVES 4/7/2014. Diabetes Update Overview of the Diabetes Epidemic in the United States. ISHP Annual Spring Meeting
Diabetes Update 2014 ISHP Annual Spring Meeting Hayley Miller MD April 13, 2014 OBJECTIVES Review diabetes guidelines. Understand diabetes management targets. Discuss current therapeutic strategies. Overview
More informationOral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy
Oral Hypoglycemics and Risk of Adverse Cardiac Events: A Summary of the Controversy Jeffrey Boord, MD, MPH Advances in Cardiovascular Medicine Kingston, Jamaica December 7, 2012 VanderbiltHeart.com Outline
More informationGLP-1 (glucagon-like peptide-1) Agonists (Byetta, Bydureon, Tanzeum, Trulicity, Victoza ) Step Therapy and Quantity Limit Criteria Program Summary
OBJECTIVE The intent of the GLP-1 (glucagon-like peptide-1) s (Byetta/exenatide, Bydureon/ exenatide extended-release, Tanzeum/albiglutide, Trulicity/dulaglutide, and Victoza/liraglutide) Step Therapy
More informationMultiple Factors Should Be Considered When Setting a Glycemic Goal
Multiple Facts Should Be Considered When Setting a Glycemic Goal Patient attitude and expected treatment effts Risks potentially associated with hypoglycemia, other adverse events Disease duration Me stringent
More informationNewer Drugs in the Management of Type 2 Diabetes Mellitus
Newer Drugs in the Management of Type 2 Diabetes Mellitus Dr. C. Dinesh M. Naidu Professor of Pharmacology, Kamineni Institute of Medical Sciences, Narketpally. 1 Presentation Outline Introduction Pathogenesis
More informationType 2 Diabetes: Where Do We Start with Treatment? DIABETES EDUCATION. Diabetes Mellitus: Complications and Co-Morbid Conditions
Diabetes Mellitus: Complications and Co-Morbid Conditions ADA Guidelines for Glycemic Control: 2016 Retinopathy Between 2005-2008, 28.5% of patients with diabetes 40 years and older diagnosed with diabetic
More informationWhat s New in Diabetes Treatment. Disclosures
What s New in Diabetes Treatment Shiri Levy M.D. Henry Ford Hospital Senior Staff Physician Service Chief, West Bloomfield Hospital Endocrinology, Metabolism, Bone and Mineral Disorders Disclosures None
More informationComparative Effectiveness and Safety of Diabetes Medications for Adults with Type 2 Diabetes
Draft Comparative Effectiveness Review Comparative Effectiveness and Safety of Diabetes Medications for Adults with Type Diabetes Prepared for: Agency for Healthcare Research and Quality U.S. Department
More informationType 2 Diabetes Mellitus 2011
2011 Michael T. McDermott MD Director, Endocrinology and Diabetes Practice University of Colorado Hospital Michael.mcdermott@ucdenver.edu Diabetes Mellitus Diagnosis 2011 Diabetes Mellitus Fasting Glucose
More informationWayne Gravois, MD August 6, 2017
Wayne Gravois, MD August 6, 2017 Americans with Diabetes (Millions) 40 30 Source: National Diabetes Statistics Report, 2011, 2017 Millions 20 10 0 1980 2009 2015 2007 - $174 Billion 2015 - $245 Billion
More informationSociety for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery
Society for Ambulatory Anesthesia Consensus Statement on Perioperative Blood Glucose Management in Diabetic Patients Undergoing Ambulatory Surgery Girish P. Joshi, MB BS, MD, FFARCSI Anesthesia & Analgesia
More informationModulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes. Overview. Prevalence of Overweight in the U.S.
Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Geneva Clark Briggs, PharmD, BCPS Overview Underlying defects with Type 2 diabetes Importance of managing postprandial glucose
More informationYOU HAVE DIABETES. Angie O Connor Community Diabetes Nurse Specialist 25th September 2013
YOU HAVE DIABETES Angie O Connor Community Diabetes Nurse Specialist 25th September 2013 Predicated 2015 figures are already met 1 in 20 have diabetes:1in8 over 60years old Definite Diagnosis is key Early
More informationAbbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone
Index Abbreviations DPP-IV dipeptidyl peptidase IV DREAM Diabetes REduction Assessment with ramipril and rosiglitazone Medication GAD glutamic acid decarboxylase GLP-1 glucagon-like peptide 1 NPH neutral
More informationTREATMENT OF DIABETES AFTER METFORMIN GREGG GERETY, MD ALBANY MEDICAL COLLEGE, DIVISION OF COMMUNITY ENDOCRINOLOGY JULY 14, 2017
TREATMENT OF DIABETES AFTER METFORMIN GREGG GERETY, MD ALBANY MEDICAL COLLEGE, DIVISION OF COMMUNITY ENDOCRINOLOGY JULY 14, 2017 Outline Review treatment algorithms from ADA/ EASD & ACE/AACE. Review positive
More informationThe Many Faces of T2DM in Long-term Care Facilities
The Many Faces of T2DM in Long-term Care Facilities Question #1 Which of the following is a risk factor for increased hypoglycemia in older patients that may suggest the need to relax hyperglycemia treatment
More informationInitiating Injectable Therapy in Type 2 Diabetes
Initiating Injectable Therapy in Type 2 Diabetes David Doriguzzi, PA C Learning Objectives To understand current Diabetes treatment guidelines To understand how injectable medications fit into current
More informationJulie White, MS Administrative Director Boston University School of Medicine Continuing Medical Education
MENTOR QI Diabetes Performance Improvement Initiative, Getting Patients to Goal in Glycemic Control: Current Data Julie White, MS Administrative Director Boston University School of Medicine Continuing
More informationWhat s New on the Horizon: Diabetes Medication Update
What s New on the Horizon: Diabetes Medication Update Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors, and what s coming Revised ADA/EASD and AACE guidelines:
More informationDrugs used in Diabetes. Dr Andrew Smith
Drugs used in Diabetes Dr Andrew Smith Plan Introduction Insulin Sensitising Drugs: Metformin Glitazones Insulin Secretagogues: Sulphonylureas Meglitinides Others: Acarbose Incretins Amylin Analogues Damaglifozin
More informationModulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes
Modulating the Incretin System: A New Therapeutic Strategy for Type 2 Diabetes Geneva Clark Briggs, PharmD, BCPS Adjunct Professor at University of Appalachia College of Pharmacy Clinical Associate, Medical
More informationDiabetes Mellitus II CPG
1 Diabetes Mellitus II CPG Candidates for Screening Integrated Complex Care Patients: Check Yearly Prediabetes: Check Yearly No Diabetes Mellitus (DM) Risk Factors: Check at Age 45, Repeat Every 3 Years
More informationDIABETES. Mary Bruskewitz APNP, MS, BC-ADM Clinical Nurse Specialist Diabetes. November 2013
DIABETES Mary Bruskewitz APNP, MS, BC-ADM Clinical Nurse Specialist Diabetes November 2013 mbruskewitz@outlook.com Objectives Part 1 Overview of Endocrine Physiology Pathophysiology of Diabetes Diabetes
More informationUpdate on Diabetes Mellitus
Update on Diabetes Mellitus Treatment: Targeting the Incretin System Overview Underlying defects with Type 2 diabetes Importance of managing postprandial glucose control Amylin Incretin Hormones New therapies
More informationPharmacology Updates. Quang T Nguyen, FACP, FACE, FTOS 11/18/17
Pharmacology Updates Quang T Nguyen, FACP, FACE, FTOS 11/18/17 14 Classes of Drugs Available for the Treatment of Type 2 DM in the USA ### Class A1c Reduction Hypoglycemia Weight Change Dosing (times/day)
More informationObesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes
Obesity, Insulin Resistance, Metabolic Syndrome, and the Natural History of Type 2 Diabetes Genetics, environment, and lifestyle (obesity, inactivity, poor diet) Impaired fasting glucose Decreased β-cell
More informationAntihyperglycemic Agents in Diabetes. Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014
Antihyperglycemic Agents in Diabetes Jamie Messenger, PharmD, CPP Department of Family Medicine East Carolina University August 18, 2014 Objectives Review 2014 ADA Standards of Medical Care in DM as they
More informationObjectives. Recognize all available medical treatment options for diabetes. Individualize treatment and glycemic target based on patient factors
No disclosure Objectives Recognize all available medical treatment options for diabetes Individualize treatment and glycemic target based on patient factors Should be able to switch to more affordable
More information9/29/ Disclosure. Learning Objectives. Diabetes Update: Guidelines, Treatment Options & Trends
+ Diabetes Update: Guidelines, Treatment Options & Trends Melissa Max, PharmD, BC-ADM, CDE Assistant Professor of Pharmacy Practice Harding University College of Pharmacy + Disclosure Conflicts Of Interest
More informationWhat s New on the Horizon: Diabetes Medication Update. Michael Shannon, MD Providence Endocrinology, Olympia WA
What s New on the Horizon: Diabetes Medication Update Michael Shannon, MD Providence Endocrinology, Olympia WA 1 Outline of Talk Newly released and upcoming medications: the incretins, DPP-IV inhibitors,
More informationMOA: Long acting glucagon-like peptide 1 receptor agonist
Alexandria Rydz MOA: Long acting glucagon-like peptide 1 receptor agonist Increases glucose dependent insulin secretion Decreases inappropriate glucagon secretion Increases β- cell growth and replication
More informationVipul Lakhani, MD Oregon Medical Group Endocrinology
Vipul Lakhani, MD Oregon Medical Group Endocrinology Disclosures None Objectives Be able to diagnose diabetes and assess control Be able to identify appropriate classes of medications for diabetes treatment
More informationA Practical Approach to the Use of Diabetes Medications
A Practical Approach to the Use of Diabetes Medications Juan Pablo Frias, M.D., FACE President, National Research Institute, Los Angles, CA Clinical Faculty, University of California, San Diego, CA OUTLINE
More informationA New Therapeutic Strategey for Type II Diabetes: Update 2008
Live, One Hour Webinar A New Therapeutic Strategey for Type II Diabetes: Update 2008 Geneva Clark Briggs, PharmD, BCPS Adjunct Professor at University of Appalachia College of Pharmacy in Grundy, Virginia.
More informationMae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville
Mae Sheikh-Ali, M.D. Assistant Professor of Medicine Division of Endocrinology University of Florida College of Medicine- Jacksonville Pathogenesis of Diabetes Mellitus (DM) Criteria for the diagnosis
More informationChief of Endocrinology East Orange General Hospital
Targeting the Incretins System: Can it Improve Our Ability to Treat Type 2 Diabetes? Darshi Sunderam, MD Darshi Sunderam, MD Chief of Endocrinology East Orange General Hospital Age-adjusted Percentage
More informationPharmacology Update for the Adult Patient - Newer Oral Medications for Diabetes
Pharmacology Update for the Adult Patient - Newer Oral Medications for Diabetes Brooke Hudspeth, PharmD, CDE, MLDE Director of Diabetes Prevention, Kroger Pharmacy Adjunct Assistant Professor, University
More informationDisclosure. Learning Objectives. Case. Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare
Disclosure Diabetes Update: Incretin Agents in Diabetes-When to Use Them? I have no disclosures to declare Spring Therapeutics Update 2011 CSHP BC Branch Anar Dossa BScPharm Pharm D CDE April 20, 2011
More informationDiabetes Oral Agents Pharmacology. University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D
Diabetes Oral Agents Pharmacology University of Hawai i Hilo Pre-Nursing Program NURS 203 General Pharmacology Danita Narciso Pharm D 1 Learning Objectives Understand the role of the utilization of free
More informationWhat s New in Diabetes Medications. Jena Torpin, PharmD
What s New in Diabetes Medications Jena Torpin, PharmD 1 Objectives Discuss new medications in the management of diabetes Understand the mechanism of the medications discussed Understand the side effects
More information7/8/2016. Sol Jacobs MD, FACE Division of Endocrinology Emory University School of Medicine
Sol Jacobs MD, FACE Division of Endocrinology Emory University School of Medicine Participation in investigator initiated clinical research supported by: Merck Boehringer Ingelheim Novo Nordisk Astra Zeneca
More informationType II Diabetes Improving Blood Sugar Control. Geneva Clark Briggs, Pharm.D., BCPS
Type II Diabetes Improving Blood Sugar Control Geneva Clark Briggs, Pharm.D., BCPS Overview Importance of glucose control State of control Review available therapies Helping patients achieve control The
More informationDiabetes Treatment Update
Diabetes Treatment Update Timothy C. Evans, MD PhD FACP University of Washington Department of Medicine Disclosure: Dr. Evans has no significant financial interest in any of the products or manufacturers
More informationManagement of Hyperglycemia in Type 2 Diabetes Celeste C. Thomas MD, MS
Management of Hyperglycemia in Type 2 Diabetes Celeste C. Thomas MD, MS Disclosures In compliance with the accrediting board policies, the American Diabetes Association requires the following disclosure
More informationManagement of Type 2 Diabetes
Management of Type 2 Diabetes Pathophysiology Insulin resistance and relative insulin deficiency/ defective secretion Not immune mediated No evidence of β cell destruction Increased risk with age, obesity
More informationAge-adjusted Percentage of U.S. Adults Who Were Obese or Who Had Diagnosed Diabetes
Age-adjusted Percentage of U.S. Adults Who Were Obese or Who Had Diagnosed Diabetes Obesity (BMI 30 kg/m 2 ) 1994 2000 2009 No Data 26.0% Diabetes 1994 2000 2009
More informationManagement of Type 2 Diabetes. Why Do We Bother to Achieve Good Control in DM2. Insulin Secretion. The Importance of BP and Glucose Control
Insulin Secretion Management of Type 2 Diabetes DG van Zyl Why Do We Bother to Achieve Good Control in DM2 % reduction 0-5 -10-15 -20-25 -30-35 -40 The Importance of BP and Glucose Control Effects of tight
More informationRPCC Pharmacy Forum. The Type 2 Diabetes Issue. Type 2 Diabetes: The Basics
Nov/Dec 2015 Issue 11 RPCC Pharmacy Forum Special Interest Articles: Diabetes Medication Chart Insulin Chart Afreeza Did you know? Exanatide, marketed as Byetta, is the synthetic form of exendin-4, which
More informationPractical Strategies for the Clinical Use of Incretin Mimetics CME/CE. CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010
Practical Strategies for the Clinical Use of Incretin Mimetics CME/CE Robert R. Henry, MD Authors and Disclosures CME/CE Released: 09/15/2009; Valid for credit through 09/15/2010 Introduction Type 2 diabetes
More information3/8/2011. Julie M. Sease, Pharm D, BCPS, CDE Associate Professor of Pharmacy Practice Presbyterian College School of Pharmacy
Summarize revisions to the 2011 American Diabetes Association clinical practice guidelines. Evaluate bromocriptine as a therapeutic option in the management of type 2 diabetes. Compare and contrast the
More informationUnderstanding Diabetes and Insulin Delivery Systems
Page 1 This program has been supported by an educational grant from Sanofi Aventis Scott K. Stolte, Pharm.D. Associate Dean, Academic Affairs Bernard J. Dunn School of Pharmacy Shenandoah University Winchester,
More informationJoslin Diabetes Center Joslin Diabetes Forum 2013: The Impact of Comorbidities on Glucose Control Scenario 2: Reduced Renal Function
Scenario 2: Reduced Renal Function 62 y.o. white man with type 2 diabetes for 18 years Hypertension and hypercholesterolemia Known proliferative retinopathy Current medications: Metformin 1000 mg bid Glyburide
More informationAgenda. Indications Different insulin preparations Insulin initiation Insulin intensification
Insulin Therapy F. Hosseinpanah Obesity Research Center Research Institute for Endocrine sciences Shahid Beheshti University of Medical Sciences November 11, 2017 Agenda Indications Different insulin preparations
More informationNATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE. Single Technology Appraisal. Canagliflozin in combination therapy for treating type 2 diabetes
NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE Single Technology Appraisal Canagliflozin in combination therapy for Final scope Remit/appraisal objective To appraise the clinical and cost effectiveness
More informationGlucose Control drug treatments
Glucose Control drug treatments It should be noted that glitazones are under suspicion of precipitating acute cardiac events and current recommendations contraindicate the use of glitazones in patients
More information9/12/2014. Main Pathophysiological Defect in T1DM. Main Pathophysiological Defects in T2DM. Personalizing Diabetes Care: The Alphabet Soup of Options
9/12/2014 Baptist Health South Florida 13th Annual Primary Focus Symposium June 28, 2014 Silvio Inzucchi MD Section of Endocrinology Yale University School of Medicine Half-Century of HTN & T2DM Medications
More informationIt is estimated that approximately 20.8 million Americans
FORMULARY MANAGEMENT Managed Care Perspective on Three New Agents for Type 2 Diabetes Shawna VanDeKoppel, PharmD; Hae Mi Choe, PharmD, CDE; and Burgunda V. Sweet, PharmD, FASHP ABSTRACT BACKGROUND: Despite
More informationDiabesity. Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs
Diabesity Metabolic dysfunction that ranges from mild blood glucose imbalance to full fledged Type 2 DM Signs Abdominal obesity Low HDL, high LDL, and high triglycerides HTN High blood glucose (F>100l,
More informationDiabetes: Inpatient Glucose control
Diabetes: Inpatient Glucose control Leanne Current, PharmD, BCPS This activity is funded through the Medicaid section 1115(a) Demonstration Texas Healthcare Transformation and Quality Improvement Program
More informationComprehensive Diabetes Treatment
Comprehensive Diabetes Treatment Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism The George Washington University School of Medicine Diabetes
More informationTreatment Options for Diabetes: An Update
Treatment Options for Diabetes: An Update A/Prof. Marg McGill Manager, Diabetes Centre Dr. Ted Wu Staff Specialist Endocrinologist Diabetes Centre Centre of Health Professional Education Education Provider
More informationDiabetes mellitus. Treatment
Diabetes mellitus Treatment Recommended glycemic targets for the clinical management of diabetes(ada) Fasting glycemia: 80-110 mg/dl Postprandial : 100-145 mg/dl HbA1c: < 6,5 % Total cholesterol: < 200
More informationMaking Sense of Mediations for Diabetes
Making Sense of Mediations for Diabetes Lisa Kroon, PharmD, CDE Professor of Clinical Pharmacy UCSF School of Pharmacy Diabetes Mellitus: U.S. Impact Source: ADA; released June 10, 2014 ~1-1.5 Million
More informationDiabetes Mellitus in Older Adults. Presenter Disclosure Information
Diabetes Mellitus in Older Adults Medha Munshi, M.D. Joslin Diabetes Center Beth Israel Deaconess Medical Center Harvard Medical School Presenter Disclosure Information Medha Munshi Research grant from
More informationJoslin Diabetes Center Advances in Diabetes and Thyroid Disease 2013 Noninsulin Treatment of Diabetes: What the PCP Needs to Know
Non Insulin Treatment of Type 2 Diabetes: What the PCP Needs to Know Martin J. Abrahamson, MD Senior Vice President for Medical Affairs Joslin Diabetes Center Associate Professor of Medicine Harvard Medical
More informationChanging Diabetes: The time is now!
Midwest Cardiovascular Research Foundation Welcomes DANITA HARRISON, ARNP Ms. Harrison discloses speaking relationships with Lilly, Novo Nordisk and Pfizer. Changing Diabetes: The time is now! Danita Harrison
More informationManagement of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach Update to a Position Statement of the American Diabetes Association (ADA) and the European Association f the Study of Diabetes
More informationIncretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors
Incretin-based Therapies for Type 2 Diabetes Comparisons Between Glucagon-like Peptide-1 Receptor Agonists and Dipeptidyl Peptidase-4 Inhibitors Timothy Bailey, MD, FACE, CPI Director, AMCR Institute,
More informationDipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol
Dipeptidyl-Peptidase 4 (DPP-4) Inhibitors Drug Class Prior Authorization Protocol Line of Business: Medicaid P&T Approval Date: February 21, 2018 Effective Date: April 1, 2018 This policy has been developed
More informationPre-diabetes. Pharmacological Approaches to Delay Progression to Diabetes
Pre-diabetes Pharmacological Approaches to Delay Progression to Diabetes Overview Definition of Pre-diabetes Risk Factors for Pre-diabetes Clinical practice guidelines for diabetes Management, including
More informationDiabetes Mellitus. Intended Learning Objectives:
Intended Learning Objectives: Diabetes Mellitus 1. Compare and contrast the differences between the drug therapy recommendations of several of the latest and leading diabetes guidelines. 2. Assess the
More informationNew Drug Evaluation: Dulaglutide
Copyright 2012 Oregon State University. All Rights Reserved Drug Use Research & Management Program Oregon State University, 500 Summer Street NE, E35, Salem, Oregon 97301-1079 Phone 503-947-5220 Fax 503-947-1119
More informationBrigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol
Brigham and Women s Hospital Type 2 Diabetes Management Program Physician Pharmacist Collaborative Drug Therapy Management Protocol *Please note that this guideline may not be appropriate for all patients
More informationHot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care
Hot Topics: The Future of Diabetes Management Cutting Edge Medication and Technology-Based Care Mary Jean Christian, MA, MBA, RD, CDE Diabetes Program Coordinator UC Irvine Health Hot Topics: Diabetes
More informationDIABETES. overview of pharmacologic agents used in the management of. Overview 4/3/2014 OBJECTIVES. Injectable Agents
overview of pharmacologic agents used in the management of DIABETES Kyle Roberts, Pharm.D. PGY-1 Pharmacy Resident Saint Alphonsus RMC 1. List the different classes of diabetes medications, including the
More informationJonathan Stoehr, MD PhD Endocrinology, Diabetes, Metabolism and Nutrition Virginia Mason Medical Center Seattle, WA 2012 Virginia Mason Medical
Jonathan Stoehr, MD PhD Endocrinology, Diabetes, Metabolism and Nutrition Virginia Mason Medical Center Seattle, WA There is no conflict of interest that could be perceived as prejudicing the impartiality
More informationCANA DAPA EMPA. Change in Baseline Body Weight (kg) *Doses evaluated in studies cited: CANA=100 or 300 mg, DAPA=5 or 10 mg, EMPA=10 or 25 mg.
CANA DAPA EMPA Change in Baseline Body Weight (kg) 2 1 0-1 -2-3 -4-5 PBO SGLT2 inhibitor (low dose)* SGLT2 inhibitor (high dose)* *Doses evaluated in studies cited: CANA=100 or 300 mg, DAPA=5 or 10 mg,
More informationDM Fundamentals Class 4 Meds for Type 2
DM Fundamentals Class 4 Meds for Type 2 Beverly Thomassian, RN, MPH, BC ADM, CDE President, Diabetes Education Services Copyright 1999 2015, Diabetes Education Services, All Rights Reserved. Diabetes Meds
More informationMultiple Small Feedings of the Mind: Diabetes. Sonja K Fredrickson, MD, BC-ADM March 7, 2014
Multiple Small Feedings of the Mind: Diabetes Sonja K Fredrickson, MD, BC-ADM March 7, 2014 Question 1: Setting A1c Goals Describe the evidence based approach to determining the target HgbA1c in different
More informationGlyceamic control is indicated by 1. Fasting blood sugar less than 126 mg/dl 2. Random blood sugar 3. HbA1c less than 6.5 % Good glycaemic control
Glyceamic control is indicated by 1. Fasting blood sugar less than 126 mg/dl 2. Random blood sugar 3. HbA1c less than 6.5 % Good glycaemic control can prevent many of early type 1 DM(in DCCT trail ). UK
More informationType. Diabetes Drugs. A Review
Type Diabetes is a common diagnosis for home care patients. Diabetes drugs are now available that target the multiple defects of metabolism that characterize Type 2 diabetes. Understanding the wide variety
More informationCardiovascular Benefits of Two Classes of Antihyperglycemic Medications
Cardiovascular Benefits of Two Classes of Antihyperglycemic Medications Nathan Woolever, Pharm.D., Resident Pharmacist Pharmacy Grand Rounds November 6 th, 2018 Franciscan Healthcare La Crosse, WI 2017
More informationDiabetes 2013: Achieving Goals Through Comprehensive Treatment. Session 2: Individualizing Therapy
Diabetes 2013: Achieving Goals Through Comprehensive Treatment Session 2: Individualizing Therapy Joshua L. Cohen, M.D., F.A.C.P. Professor of Medicine Interim Director, Division of Endocrinology & Metabolism
More informationEarly treatment for patients with Type 2 Diabetes
Israel Society of Internal Medicine Kibutz Hagoshrim, June 22, 2012 Early treatment for patients with Type 2 Diabetes Eduard Montanya Hospital Universitari Bellvitge-IDIBELL CIBERDEM University of Barcelona
More informationDiabetes in Pregnancy
Diabetes in Pregnancy Ebony Boyce Carter, MD, MPH Division of Maternal Fetal Medicine Washington University School of Medicine Disclosures I have no financial disclosures to report. Objectives Review the
More informationUpdate on Insulin-based Agents for T2D
Update on Insulin-based Agents for T2D Injectable Therapies for Type 2 Diabetes Mellitus (T2DM) and Obesity This presentation will: Describe established and newly available insulin therapies for treatment
More informationCE on SUNDAY Miami, FL May 31, 2009
CE on SUNDAY Miami, FL May 31, 2009 Date: Sunday, May 31, 2009 Time: 1:15 PM 2:15 PM Location: Doubletree Miami Mart/Airport Hotel Title: Speaker(s): Understanding Diabetes and Insulin Delivery Systems
More informationTable 1. Antihyperglycemic agents for use in type 2 diabetes
Table 1. Antihyperglycemic agents for use in type 2 diabetes DRUG IN ALPHA-GLUCOSIDASE INHIBITOR: inhibits pancreatic alpha-amyle and intestinal alpha-glucoside Acarbose (Glucobay) 0.6% Negligible Not
More informationThe Community Pharmacist s Role in Diabetes Treatment
CONTINUING EDUCATION The Community Pharmacist s Role in Diabetes Treatment By Kimberly Ference, PharmD U pon completion of this activity, the pharmacist should be able to achieve these directives: 1. Describe
More informationJoshua Settle, PharmD Clinical Pharmacist Baptist Medical Center South ALSHP Fall Meeting September 30, 2016
Joshua Settle, PharmD Clinical Pharmacist Baptist Medical Center South jjsettle@baptistfirst.org ALSHP Fall Meeting September 30, 2016 Objectives Describe the current information concerning newly approved
More informationNo disclosures. Diabetes Test Topics. Case #1. Diabetes Family Medicine Board Review: Improving Clinical Care Across the Lifespan
Diabetes Family Medicine Board Review: Improving Clinical Care Across the Lifespan No disclosures Sarah Kim, MD Assistant Clinical Professor of Clinical Medicine, UCSF Division of Endocrinology, SFGH March
More informationCardiovascular Management of a Patient with Diabetes
Cardiovascular Management of a Patient with Diabetes Dr Jeremy Krebs Clinical Leader Endocrinology and Diabetes Wellington Hospital Summary People with diabetes take a lot of medication Compliance and
More informationJeffery Davies, DO, MPH, FACOEP ACOEP Chicago, IL October Your DM patient is ready for discharge, now what?
Jeffery Davies, DO, MPH, FACOEP ACOEP Chicago, IL October 2018 Your DM patient is ready for discharge, now what? Financial Disclosures None Objectives 1. Understand follow up patterns/capability of patients
More informationPathogenesis of Type 2 Diabetes
9/23/215 Multiple, Complex Pathophysiological Abnmalities in T2DM incretin effect gut carbohydrate delivery & absption pancreatic insulin secretion pancreatic glucagon secretion HYPERGLYCEMIA? Pathogenesis
More informationEnrique Caballero, MD Director, Latino Diabetes Initiative Joslin Diabetes Center Harvard Medical School
New Diabetes Treatments Embryonic Stem Cells (ESC) Ectoderm Mesoderm Enrique Caballero, MD Director, Latino Diabetes Initiative Joslin Diabetes Center Harvard Medical School ESC Endoderm Pancreas Islet
More informationNATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE. Proposed Health Technology Appraisal
NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE Proposed Health Technology Appraisal Dapagliflozin in combination therapy for the Final scope Remit/appraisal objective To appraise the clinical and
More informationPancreatic b-cell Dysfunction in Type 2 Diabetes ZIAD KAHWASH, M.D. Insulin resistance: Defects in Insulin Signaling
Plasma insulin (mu/ml) ZIAD KAHWASH, M.D. resistance: Defects in Signaling Increased glucose production Glucose Insufficient glucose disposal X Liver glucagon insulin Pancreas Peripheral tissues (skeletal
More informationNewer and Expensive treatment of diabetes. Endocrinology Visiting Associate Professor Institute of Medicine TUTH
Newer and Expensive treatment of diabetes Jyoti Bhattarai MD Endocrinology Visiting Associate Professor Institute of Medicine TUTH Four out of every five people with diabetes now live in developing countries.
More informationOral and Injectable Non-insulin Antihyperglycemic Agents
Appendix 5: Diabetes Education and Medical Management in Adults with Diabetes Oral and Injectable Non-insulin s This directive will be implemented by RPhs, RNs or RDs who have been deemed authorized implementers.
More information